Urination problems affect millions of men worldwide, often developing so gradually that many dismiss early warning signs.

The FDA has approved Gemtesa® for men with overactive bladder symptoms receiving pharmacological therapy for BPH.

Photo: Dr. Jennifer Kuo. Courtesy of Trinity Health Community News Dr. Jennifer Kuo, a urologist with Trinity Health IHA ...

Many people believe that urinary tract infections (UTIs) and incontinence are more common in women, but they can also affect ...

Sumitomo Pharma's Gemtesa (vibegron) has been approved by the U.S. Food and Drug Administration for men with overactive ...

You had obstruction of the urinary tract. In adult men, the most common cause by far is prostate enlargement. The entire prostate needn’t be enlarged, only the part where the urethra is, which can get ...

Gemtesa (vibegron) has been approved by the U.S. Food and Drug Administration for men with overactive bladder (OAB) symptoms ...

[7] Among men with both DO and BOO that did not improve on alpha-blocker monotherapy, 73% did show symptomatic improvement after 3 months of tolterodine treatment. Urge urinary incontinence ...

The Urgent PC Modulation System first received FDA 510K marketing clearance (K052025) in 2005 for the treatment of urinary urgency, urinary frequency, and urge incontinence. The FDA considers the ...

Additionally, the average daily number of urge urinary incontinence episodes was ... of Gemtesa is an important milestone for the men with unresolved symptoms of OAB while being treated for ...